Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05686044 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
A Phase 2 study, sponsored by Annovis Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 351
- Enrollment target
NCT05686044 is a Phase 2 study that has completed, run by Annovis Bio. The registered enrollment target is 351 participants.
The verdict
NCT05686044, a Phase 2 study, has completed, sponsored by Annovis Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 351 participants
- Enrollment target
Study Summary
The purpose of this study is to measure efficacy and safety of three different doses of buntanetap/Posiphen compared with placebo in participants with mild to moderate Alzheimer's disease. Study details include: The double-blind treatment duration will include a screening period of up to 42 days followed by 12 weeks of treatment at home. The study duration will be 4-5 months. There will be 4 in-clinic visits and 1 phone call.
Interventions
- DRUG Placebo
- DRUG Buntanetap/Posiphen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2024-02-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05686044
The ClinicalTrials.gov registry entry for NCT05686044 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 351 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Annovis Bio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05686044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05686044 about?
NCT05686044 is a clinical study titled "A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD". The purpose of this study is to measure efficacy and safety of three different doses of buntanetap/Posiphen compared with placebo in participants with mild to moderate Alzheimer's disease. Study details include: The double-blind treatment duration will include a screening period of up to 42 days f...
What is the current status of trial NCT05686044?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 351 participants. The study started on 2023-04-01. Estimated completion is 2024-02-13.
What interventions are being tested in trial NCT05686044?
The interventions under investigation include: Placebo (DRUG), Buntanetap/Posiphen (DRUG).
Who is sponsoring clinical trial NCT05686044?
This trial is sponsored by Annovis Bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.